Assessing Surmodics: Insights From 5 Financial Analysts
Portfolio Pulse from Benzinga Insights
Surmodics (NASDAQ:SRDX) has been analyzed by 5 analysts over the past three months, showing a range of ratings from bullish to bearish. The average 12-month price target is $49.4, with a high of $71.00 and a low of $43.00. Recent analyst actions include maintaining, lowering, and announcing new ratings, reflecting evolving market conditions and company performance. Surmodics has shown strong financial metrics, including a 17.5% revenue growth rate, a net margin of 0.77%, and a debt-to-equity ratio of 0.27.
May 30, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Surmodics has been analyzed by 5 analysts, showing a range of ratings from bullish to bearish. The average 12-month price target is $49.4, with a high of $71.00 and a low of $43.00. Recent analyst actions include maintaining, lowering, and announcing new ratings, reflecting evolving market conditions and company performance.
The diverse range of analyst ratings and recent actions indicate mixed sentiment towards Surmodics. The average price target has decreased, reflecting some bearish sentiment. However, strong financial metrics such as revenue growth and net margin provide a counterbalance, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100